Karin Govaert
The fact that the CPCT, together with Hartwig Medical Foundation, has managed to bundle data, knowledge and expertise from almost all Dutch hospitals is unique and now also deserves international attention.
Back to newsMore news
GLOW: working toward more treatment options for glioblastoma
The outlook for patients with glioblastoma has been unfavorable for years, and treatment options remain limited. That is a reason …
Hartwig Medical Foundation adapts working method and continues work
In this uncertain time when we are trying to prevent the spread of the Coronavirus, we have adapted our working …
Biomarkers Reveal Which Cancer Patients Won’t Benefit From Treatment
Researchers from Vall d’Hebron Institute of Oncology identify genomic signals predicting non-response to cancer therapies in collaboration with Hartwig Medical …
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.